FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Holding(s) in Company
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
|
GB0009895292
|
Issuer Name
|
ASTRAZENECA PLC
|
UK or Non-UK Issuer
|
UK
|
2. Reason for Notification
|
An acquisition or disposal of voting rights
|
3. Details of person subject to the notification
obligation
Name
|
The Capital Group Companies, Inc.
|
City of registered office (if applicable)
|
Los Angeles
|
Country of registered office (if applicable)
|
USA
|
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject
to the notification obligation, above
|
|
City of registered office (if applicable)
|
|
Country of registered office (if applicable)
|
|
5. Date on which the threshold was crossed or reached
|
13-Nov-2025
|
6. Date on which Issuer notified
|
15-Nov-2025
|
7. Total positions of person(s) subject to the notification
obligation
|
|
% of voting rights attached to shares (total of 8.A)
|
% of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total of both in % (8.A + 8.B)
|
Total number of voting rights held in issuer
|
|
Resulting
situation on the date on which threshold was crossed or
reached
|
5.017815
|
0.000000
|
5.017815
|
77811893
|
|
Position
of previous notification (if applicable)
|
4.997854
|
0.000000
|
4.997854
|
|
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
|
GB0009895292 Common
Stock
|
|
65749228
|
|
4.239936
|
|
US0463531089
Depository Receipt
|
|
12062665
|
|
0.777879
|
|
Sub Total 8.A
|
77811893
|
5.017815%
|
||
8B1. Financial Instruments according to (DTR5.3.1R.(1)
(a))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
|
|
|
|
|
|
Sub
Total 8.B1
|
|
|
|
|
8B2. Financial Instruments with similar economic effect according
to (DTR5.3.1R.(1) (b))
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
|
|
Sub
Total 8.B2
|
|
|
|
||
9. Information in relation to the person subject to the
notification obligation
|
2. Full chain of controlled undertakings through which the voting
rights and/or the financial instruments are effectively held
starting with the ultimate controlling natural person or legal
entities (please add additional rows as necessary)
|
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
The
Capital Group Companies, Inc.
|
Capital
Research and Management Company
|
|
|
|
|
The
Capital Group Companies, Inc.
|
Capital
International, Inc.
|
|
|
|
|
The
Capital Group Companies, Inc.
|
Capital
Group Private Client Services, Inc.
|
|
|
|
|
The
Capital Group Companies, Inc.
|
Capital
International Sarl
|
|
|
|
|
The
Capital Group Companies, Inc.
|
Capital
International Limited
|
|
|
|
10. In case of proxy voting
Name of the proxy holder
|
|
The number and % of voting rights held
|
|
The date until which the voting rights will be held
|
|
11. Additional Information
|
The Capital Group Companies, Inc. ("CGC") is the parent company of
Capital Research and Management Company ("CRMC") and Capital Bank
& Trust Company ("CB&T"). CRMC is a U.S.-based investment
management company that serves as investment manager to the
American Funds family of mutual funds, other pooled investment
vehicles, as well as individual and institutional clients. CRMC and
its investment manager affiliates manage equity assets for various
investment companies through three divisions, Capital Research
Global Investors, Capital International Investors and Capital World
Investors. CRMC is the parent company of Capital Group
International, Inc. ("CGII"), which in turn is the parent company
of six investment management companies ("CGII management
companies"): Capital International, Inc., Capital International
Limited, Capital International Sàrl, Capital International
K.K., Capital Group Private Client Services Inc, and Capital Group
Investment Management Private Limited. CGII management companies
primarily serve as investment managers to institutional and high
net worth clients. CB&T is a U.S.-based registered investment
adviser and an affiliated federally chartered bank.Neither CGC nor
any of its affiliates own shares of the Issuer for its own account.
Rather, the shares reported on this Notification are owned by
accounts under the discretionary investment management of one or
more of the investment management companies described
above.
|
12. Date of Completion
|
15-Nov-2025
|
13. Place Of Completion
|
Los Angeles
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 17 November 2025
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|